The partnership will integrate IDRI's RNA vaccine platform, which includes its nanostructured lipid carrier (NLC) technology, with Amyris's semi-synthetic squalene (squalene is a natural organic compound taken from shark liver oil).

Under terms of the agreement, Amyris will co-own intellectual property developed to create a COVID-19 vaccine, any rights to any combination of IDRI materials and Amyris squalene, the preclinical and phase I clinical trial data, and the clinical study report, it said.

The project is expected to conclude in the first half of 2022, according to the firm.

Amyris partners with IDRI on scalable vaccine platform
Amyris and the Infectious Disease Research Institute (IDRI) have inked a binding term sheet for the development of a planned COVID-19 RNA vaccine technology...